Overview

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Status:
Recruiting

Trial end date:
2025-07-29

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants with severe atopic dermatitis and to evaluate palatability of upadacitinib oral solution in pediatric participants (Cohorts 1 to 4 only).

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib